SGLT-2抑制剂引起糖尿病患者急性肾损伤的机制

Mechanisms of acute renal injury caused by SGLT-2 inhibitor in patients with diabetes mellitus

摘要: 钠-葡萄糖共转运蛋白-2（sodium-glucose cotransporter-2，SGLT-2）抑制剂是一种2型糖尿病（diabetes mellitus type 2，T2DM）降糖药物，大量的临床试验表明它能降低T2DM患者的心血管病死率，但越来越多的证据表明SGLT-2抑制剂的使用可能与发生急性肾损伤（acute kidney injury，AKI）的风险有关，本文就SGLT-2抑制剂引起AKI的机制做一综述，对相关机制的了解可能有助于识别有发生AKI风险的个体。

Abstract: Sodium-glucose cotransporter-2 inhibitor is a type 2 diabetes (T2DM) sugar-lowering agent.Numerous clinical trials have demonstrated that it could lower cardiovascular mortality in type 2 diabetics.As shown by growing evidence,use of SGLT-2 inhibitor was associated with the risk of acute kidney injury (AKI).This review focused upon the mechanisms by which SGLT-2 inhibitor caused AKI and assisted in identifying individuals at a risk of AKI.